Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.48 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29526133 | 0.97 | DPP4 (0.46) | DPP4DPP8DPP9GRM8GRM6 | |
| SCHEMBL29526248 | 0.93 | DPP4 (0.48) | DPP4DPP8DPP9GRM8GRM6 | |
| SCHEMBL29375582 | 0.90 | DPP4 (0.47) | DPP4DPP8DPP9PTGS1GSTK1 | |
| SCHEMBL30939436 | 0.90 | DPP4 (0.49) | DPP4DPP8DPP9GRM8GRM6 | |
| SCHEMBL19243989 | 0.89 | DPP4 (0.46) | DPP4DPP8DPP9GRM8GRM6 | |
| SCHEMBL29526885 | 0.89 | OPRM1 (0.47) | DPP4DPP8DPP9PTGS1GSTK1 | |
| SCHEMBL31675112 | 0.86 | DPP4 (0.46) | DPP4DPP8DPP9GRM8GRM6 | |
| SCHEMBL4388333 | 0.85 | DPP4 (0.59) | DPP4DPP8DPP9GRM8GRM6 | |
| SCHEMBL8529159 | 0.85 | DPP4 (0.59) | DPP4DPP8DPP9GRM8GRM6 | |
| SCHEMBL29854499 | 0.84 | CD274 (0.52) | PTGS1GSTK1PDCD1LG2CD274OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12122815-B2 | GIP receptor agonist peptide compounds and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-22 | — | — | US | claimed |
| CN-116162146-A | GIP-GLP-1 double-agonist compound | 成都奥达生物科技有限公司 | 2023-05-26 | — | — | CN | claimed |
| CN-115594753-A | Long-acting double-agonist compound | 成都奥达生物科技有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-115594752-A | Long-acting double-agonist compound | 成都奥达生物科技有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| EP-3864032-B1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | FRESENIUS KABI IPSUM S R L (IT) | 2022-11-30 | — | — | EP | claimed |
| CN-115335395-A | QD administration of GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2022-11-11 | — | — | CN | claimed |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-07-26 | — | — | US | claimed |
| US-20220227830-A1 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-07-21 | — | — | US | claimed |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-05-05 | — | — | US | claimed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | claimed |
| EP-3601329-B1 | GIP RECEPTOR ACTIVATING PEPTIDE | TAKEDA PHARMACEUTICALS CO (JP) | 2024-12-04 | — | — | EP | disclosed |
| US-12122815-B2 | GIP receptor agonist peptide compounds and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-22 | — | — | US | disclosed |
| JP-2024063019-A | GIP receptor agonist peptide compounds and uses thereof | 武田薬品工業株式会社 | 2024-05-10 | — | — | JP | disclosed |
| CN-116162146-B | GIP-GLP-1 double-agonist compound | 成都奥达生物科技有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116162146-A | GIP-GLP-1 double-agonist compound | 成都奥达生物科技有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-07-26 | — | — | US | disclosed |
| US-20220227830-A1 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-07-21 | — | — | US | disclosed |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-05-05 | — | — | US | disclosed |
| CN-114269774-A | Appetite suppressant compounds | IP2IPO创新有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | GLP1R, IAPP, VIP | DPP4 6/4885DPP8 29/4885DPP9 31/4885 |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | GLP1R, IAPP, VIP | DPP4 6/4885DPP8 29/4885DPP9 31/4885 |
| US-20220227830-A1 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, GRPR | DPP4 77/4885DPP8 80/4885DPP9 75/4885 |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, VIPR1 | DPP4 77/4885DPP8 52/4885DPP9 149/4885 |
| US-12122815-B2 | GIP receptor agonist peptide compounds and uses thereof | GIPR, GLP1R, GPR119 | DPP4 74/4885DPP8 51/4885DPP9 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.